Phase 2 trial of ozuriftamab vedotin (BA3021), a conditionally binding ROR2-ADC, in patients with heavily pretreated squamous cell carcinoma of the head and neck. Mechanisms of resistance to anti-PD1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback